As of 2026-05-22, the Relative Valuation of Genscript Biotech Corp (1548.HK) is (45.67) HKD. This relative valuation is based on P/E multiples. With the latest stock price at 13.09 HKD, the upside of Genscript Biotech Corp based on Relative Valuation is -448.9%.
The range of the Relative Valuation is (41.91) - (44.54) HKD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 22.0x - 31.8x | 27.4x |
| Forward P/E multiples | 17.9x - 23.4x | 20.5x |
| Fair Price | (41.91) - (44.54) | (45.67) |
| Upside | -420.2% - -440.3% | -448.9% |
| Date | P/E |
| 2026-05-20 | -6.86 |
| 2026-05-19 | -6.94 |
| 2026-05-18 | -7.04 |
| 2026-05-15 | -7.37 |
| 2026-05-14 | -7.63 |
| 2026-05-13 | -7.74 |
| 2026-05-12 | -7.60 |
| 2026-05-11 | -8.01 |
| 2026-05-08 | -7.98 |
| 2026-05-07 | -8.12 |
| 2026-05-06 | -7.56 |
| 2026-05-05 | -7.12 |
| 2026-05-04 | -6.98 |
| 2026-04-30 | -7.20 |
| 2026-04-29 | -7.14 |
| 2026-04-28 | -7.10 |
| 2026-04-27 | -7.14 |
| 2026-04-24 | -7.26 |
| 2026-04-23 | -7.29 |
| 2026-04-22 | -7.44 |
| 2026-04-21 | -7.56 |
| 2026-04-20 | -7.21 |
| 2026-04-17 | -7.22 |
| 2026-04-16 | -7.21 |
| 2026-04-15 | -6.98 |
| 2026-04-14 | -6.66 |
| 2026-04-13 | -6.62 |
| 2026-04-10 | -6.72 |
| 2026-04-09 | -6.68 |
| 2026-04-08 | -6.75 |
| 2026-04-02 | -6.48 |
| 2026-04-01 | -6.21 |
| 2026-03-31 | -5.74 |
| 2026-03-30 | -5.77 |
| 2026-03-27 | -5.82 |
| 2026-03-26 | -5.64 |
| 2026-03-25 | -5.77 |
| 2026-03-24 | -5.68 |
| 2026-03-23 | -5.56 |
| 2026-03-20 | -5.82 |
| 2026-03-19 | -5.91 |
| 2026-03-18 | -6.09 |
| 2026-03-17 | -6.11 |
| 2026-03-16 | -5.89 |
| 2026-03-13 | -5.82 |
| 2026-03-12 | -5.94 |
| 2026-03-11 | -5.94 |
| 2026-03-10 | -6.23 |
| 2026-03-09 | -6.13 |
| 2026-03-06 | -5.99 |